0143a79a-bac2-47c7-b65d-7e472b2b72ab
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- COAGULATION+0.400
- ANGIOGENESIS+0.300
- APICAL_SURFACE+0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
- IL6_JAK_STAT3_SIGNALING+0.300
- PANCREAS_BETA_CELLS+0.300
- TNFA_SIGNALING_VIA_NFKB+0.300
- ESTROGEN_RESPONSE_LATE+0.200
- INFLAMMATORY_RESPONSE+0.200
- KRAS_SIGNALING_DN+0.200
Top 10 suppressed
- MYC_TARGETS_V2-0.500
- E2F_TARGETS-0.400
- G2M_CHECKPOINT-0.400
- MITOTIC_SPINDLE-0.400
- PI3K_AKT_MTOR_SIGNALING-0.400
- MYC_TARGETS_V1-0.300
- PROTEIN_SECRETION-0.300
- UNFOLDED_PROTEIN_RESPONSE-0.300
- ADIPOGENESIS-0.200
- DNA_REPAIR-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG229 | — | — | 0.880 |
| 2 | SRR1797250 | — | cohortMD2 | 0.875 |
| 3 | MDT-AP-1344 | Med | Medulloblastoma | 0.858 |
| 4 | 8bcf201b-a2ac-4026-ace4-39a0d915da41 | — | — | 0.855 |
| 5 | SRR1319019 | GTEX | — | 0.854 |
| 6 | SRR662725 | GTEX | — | 0.851 |
| 7 | SRR1085662 | GTEX | — | 0.846 |
| 8 | SRR659780 | GTEX | — | 0.846 |
| 9 | SRR33532813 | — | A | 0.845 |
| 10 | SRR1317853 | GTEX | — | 0.845 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| COAGULATION | 0.400 | Binimetinib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.300 | Temsirolimus | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |
| HYPOXIA | 0.100 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.100 | Inavolisib | — uncovered |
| MYOGENESIS | 0.100 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.100 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |